spacer
home > white papers > ConsulTech GmbH - ConsulTech GmbH
WHITE PAPERS
logo_ConsulTech.jpg

ConsulTech GmbH

phone +49 30 80197111
email Info@consultech.de
web http://www.consultech.de/
email Anhaltinerstrasse 22 D-14163 Berlin

ConsulTech GmbH

ConsulTech is a consulting company founded in 1992. Since then, we have been supporting biotech-nology, pharmaceutical and medical technology companies as well as research institutions with the entire process of setting-up and executing proposals for R&D projects. In projects funded by the European Commission, ConsulTech supports the coordinator by resuming administrative tasks allow-ing coordinators and partners to fully concentrate on the scientific and technical success of the pro-ject. We solve financial and administrative issues, organise meetings, take care of the timely delivery of milestones and reports and much more.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Altasciences Acquires Sinclair Research and Continues to Expand Preclinical Platform

Laval, Quebec, January 4, 2022 – Altasciences, an integrated CRO/CDMO offering pharmaceutical and biotechnology companies a seamless solution to early-stage drug development from lead candidate selection to clinical proof of concept, announced today the completed acquisition of Sinclair Research, a preclinical CRO located in the Midwest. Complementing existing locations on the East and West Coast, the new site will facilitate even greater access to Altasciences’ preclinical services across the US.
More info >>


White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement